Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Levosalbutamol 0.63 mg + Ipratropium 500 mcg respule
Therapeutic Category
Pulmonary, Respiratory, Asthma
Dosage Form
Respule
Packaging Type
Pack
Packaging
4x5x2.5 ml
Price
₹250/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
This respule contains Levosalbutamol 0.63 mg and Ipratropium Bromide 500 mcg, a combination of a selective β2-agonist and an anticholinergic bronchodilator. It is formulated for nebulization and used to relieve bronchospasm in patients with chronic obstructive pulmonary disease (COPD) and asthma. Levosalbutamol provides quick bronchodilation, while Ipratropium enhances the bronchodilatory effect by inhibiting vagally mediated reflexes.
Patients may experience dry mouth, cough, nervousness, tremor, headache, or dizziness. Rarely, palpitations, urinary retention, or eye irritation (if nebulized mist reaches the eyes) may occur.
Indicated for the treatment of reversible bronchospasm associated with COPD, chronic bronchitis, emphysema, and moderate to severe asthma, especially in patients who require more than one bronchodilator.
Use under medical supervision. For inhalation only via nebulizer. Avoid contact with eyes. Not recommended for mixing with other nebulizer medications unless prescribed. Caution is advised in patients with glaucoma, prostatic hypertrophy, or cardiovascular disease.
Store at room temperature (15-30°C), away from direct sunlight and moisture. Keep out of reach of children.
Composition : Lactulose 15 ml contains lactulose concentrate 66.7% in 6 gm Syrup
Composition : Ayurvedic Constipation Syrup
Composition : Aceclofenac (200mg) + Rabeprazole (20mg) Capsule
Composition : Acotiamide (100mg) Tablet
Composition : Acotiamide (300mg) Tablet
Composition : Magaldrate I.P. 400mg + Simethicone I.P. 20mg (Mango & Mint Flavour)
Composition : Magaldrate I.P. 480mg + Simethicone I.P. 20mg + Oxetacaine B.P. 10mg
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This combination respule is used for the treatment of bronchospasm in conditions like asthma, COPD, wheezing, and severe respiratory distress. It combines a beta-agonist (levosalbutamol) and an anticholinergic (ipratropium), making it a strong hospital-care and respiratory nebulization segment product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from strong demand in hospitals, emergency wards, ICUs, and respiratory care units. It is widely used in nebulization therapy for acute asthma and COPD exacerbations, ensuring consistent institutional orders and high-value sales.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for respiratory and nebulization formulations with monopoly rights, quality manufacturing standards, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from hospital procurement, ICU demand, emergency usage, chronic respiratory therapy prescriptions, and steady institutional business when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this nebulization formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, product availability, and distribution support services.